Skip to content

Advertisement

  • Original clinical investigation
  • Open Access

Low dose compared to variable dose Warfarin and to Fondaparinux as prophylaxis for thromboembolism after elective hip or knee replacement surgery; a randomized, prospective study

  • 1, 4, 5, 6Email author,
  • 4,
  • 4,
  • 2, 7,
  • 2, 7,
  • 3, 7,
  • 2, 7,
  • 2, 7,
  • 4,
  • 4,
  • 1, 5 and
  • 2, 7
Thrombosis Journal201513:32

https://doi.org/10.1186/s12959-015-0062-0

©  Bern et al. 2015

  • Received: 16 March 2015
  • Accepted: 15 June 2015
  • Published:

Abstract

Background

Deep vein thrombosis (DVT) and pulmonary emboli (PE), known together as venous thromboembolic (VTE) disease remain major complications following elective hip and knee surgery. This study compares three chemoprophylactic regimens for VTE following elective primary unilateral hip or knee replacement, one of which was designed to minimize risk of post-operative bleeding.

Methods

Patients were randomized and stratified for hip vs. knee to receive A: variable dose warfarin (first dose on the night preceding surgery with subsequent target INR 2.0–2.5), B: 2.5 mg fondaparinux daily starting 6–18 h postoperatively, or C: fixed 1.0 mg dose warfarin daily starting 7 days preoperatively. All treatments continued until bilateral leg venous ultrasound day 28 ± 2 or earlier upon a VTE event. The study examined primary endpoints including leg DVT, PE or death due to VTE and secondary endpoints including effects on D-dimer, estimated blood loss (EBL) at surgery and hemorrhagic complications.

Results

Three hundred fifty-five patients were randomized. None was lost to follow-up. Taking 1.0 mg warfarin for seven days preoperatively did not prolong the prothrombin time (PT). Two patients in Arm C had asymptomatic distal DVT. One major bleed occurred in Arm B and one in Arm C (ischemic colitis). Elevated d-dimer did not predict delayed VTE for one year.

Conclusions

Fixed low dose warfarin started preoperatively is equivalent to two other standards of care under study (95 % CI: -0.0428, 0.0067 for both) as VTE prophylaxis for the patients having elective major joint replacement surgery.

Trial registration

ClinicalTrials.gov identifier # NCT00767559

FDA IND: 103,716

Keywords

  • Arthroplasty
  • Fondaparinux
  • Hip replacement
  • Knee replacement
  • Prophylaxis
  • Thrombophlebitis
  • Warfarin
  • Deep vein thrombosis
  • Pulmonary embolus

Background

When initiated prior to elective surgery low dose warfarin has been demonstrated prophylactic capacity against VTE with low risk of hemorrhage [1–14]. Warfarin when given at 1 mg per day is known to increase serum under-gamma-carboxylated osteocalcin and plasma under-gamma-carboxylated prothrombin, without change of prothrombin times or factor VII activity [15]. It is critical in this pharmacologic format that low dose warfarin be initiated prior to the surgical trauma, thus allowing time for warfarin to partially suppress the carboxylation of glutamic acid residues attached to the cores of factors II, VII, IX and X [16]. This sequentially reduces their calcium ion dependent function [16–21] It is this mechanism which we believe reduces the efficiency of calcium binding, thus slowing the efficiency of clotting but not so much as to cause full anticoagulation.

This study is a continuum of studies predicated upon the concept that the clotting system can be kept in a homeostatic balance, making it possible to avoid added risk of bleeding while protecting patients from thromboembolism [1–14]. Among these studies was a prospective pilot study of 100 patients in which patients planning total hip replacement were randomized between two arms, one with warfarin starting with 5.0 mg the night prior to surgery followed by variable dose warfarin (target PT 1.3–1.5 x normal) and the other using 1.0 mg of warfarin beginning seven days prior to surgery, and both continuing for 30–45 days. There was no difference for incidence of venous thrombosis [8]. Another was a retrospective study of patients undergoing primary (n = 833) or revision (n = 170) hip replacement arthroplasty who received 1.0 mg of warfarin for seven days prior to surgery, variable dose warfarin while in hospital (target INR 1.5–2.0) followed by1.0 mg daily until follow-up at 30–45 days. Of 1,003 patients, only 3 (0.3 %) had symptomatic VTE [11].

This current investigator-initiated, single-institution, prospective, randomized, open-label assessor-blind study study compared fixed low dose of warfarin to two control arms as chemoprophylaxis against VTE among patients undergoing elective primary hip or knee replacement. Fixed low dose warfarin was initiated 7 days prior to surgery so as to allow the necessary time for its effects to be in place by the time of surgery. All patients received the same optimal non-pharmacologic support. We hypothesized that the three chemotherapeutic regimens would yield equivalent clinical findings for these patients. If confirmed as effective the fixed low dose regimen should have minimal hemorrhagic potential and would require less laboratory support, but with less cost than the modern novel oral anticoagulants that are also available [22].

Methods

Research design

This was a prospective, randomized three-arm study including two control arms (warfarin and fondaparinux in standard doses) and a third arm using warfarin at 1.0 mg per day starting seven days before surgery. Therapy was continued until a VTE event occurred or until 28 ± 2 days from day of surgery when bilateral leg ultrasounds were performed. (see Table 1) All patients were called 6 and 12 months following their surgery to detect any delayed complications or VTE events.
Table 1

Research design

ARM A:

 

Variable dose warfarin:

 
 

5.0 mg beginning the night before surgery, followed by 5.0 mg the PM of surgery, and then variable daily dose, (target INR 2.0-2.5) until day 28 ± 2 follow-up.

ARM B:

 

Fondaparinux:

 
 

2.5 mg daily starting 6 or more hours following surgery, but no later than 6 AM the next day, or 6-8 h after epidural catheter removal; continued until day 28 ± 2

ARM C:

 

Fixed low dose warfarin

 
 

1.0 mg daily beginning 7 days preoperatively, and continued at 1.0 mg daily until day 28 ± 2 follow-up.

Bilateral, full leg, venous Doppler and ultrasound analysis 28 ± 2 following surgery

Follow-up phone calls at 6 and 12 months following surgery

The primary endpoint was composite DVT, PE or death due to VTE. Secondary endpoints included frequency of proximal vs. distal DVT, estimated blood loss (EBL) at surgery, and hemorrhagic complications.

The hospital’s Institutional Review Board (IRB) approved this study. All patients gave signed informed consent.

Randomization

Total randomized patient allocations were to be at 1:1:1 ratio for each arm at end of study. The randomization was stratified for hip vs. knee surgery. A member of the pharmacy department pulled randomized cards as prepared by the statisticians. The results were communicated to the Clinical Research Coordinator (CRC), who then shared the results with the patients. Notice of consent was place in the patient’s chart, along with pre-and postoperative orders. Study diaries were then given to all consenting patients.

Patient recruitment

Participants were recruited from among patients over 20 years of age planning elective primary unilateral total hip or knee replacement surgery at an orthopedic specialty hospital. Exclusion criteria are demonstrated in Table 2. There were no gender, ethnicity or race-based restrictions.
Table 2

Exclusion criteria

1. Abnormal platelet count, prothrombin time (PT) or partial thromboplastin time (PTT)

2. Surgery for acute fracture (<4 weeks), septic joint, or extraction arthroplasty

3. History of VTE or documented hypercoagulation syndrome

4. Increased risk of hemorrhage, as from active gastric ulcer or urinary tract bleed within the last year

5. Hemorrhagic stroke; brain, spinal, or ophthalmologic surgery in previous 6 months

6. Liver enzymes or bilirubin greater than 2 x normal

7. Decreased renal function with GFR <30 ml/min.

8. Cancer in last year, other than localized cancers of the skin

9. Requires chronic anticoagulation

10. Requires chronic platelet function suppressive therapy

11. Prior adverse reaction to any of the study drugs

12. Uncontrolled hypertension

13. BMI >42

14. Pregnancy

Surgical and postoperative care

Eleven orthopedic surgeons participated in this study. The surgical, anesthesia and postoperative procedures were according to the standardized procedures used in our hospital. Patients had early post-operative ambulation. All patients wore pneumatic compression stockings while in-patient. Elastic compression stockings were prescribed to be used after discharge until the follow-up ultrasounds. Hydroxyethyl starch (HES) 6 % was allowed intraoperatively for case specific reasons. Use of platelet function suppressive drugs, such a nonsteriodal anti-inflamatory drugs (NSAIDs), was discouraged but not prohibitied by the protool.

Laboratory monitoring

All patients receiving warfarin in hospital had PT measured daily. Thereafter, patients discharged on variable dose warfarin had PT measurements twice per week. Warfarin doses were prescribed by the hospital’s Coumadin Hotline personnel with target International Normalized Ratio (INR) 2.0–2.5. The patients on the 1 mg warfarin study arm had PT measured weekly. D-dimer was tested by flocculation and by quantitative assays upon admission and at the 28 ± 2 day follow-up visits with the results are reported as negative (0–500 μg/mL), indeterminate (500–1,000 μg/mL), or positive (>1,000 μg/mL). (Diagnostica Stago, American Bioproducts Co., Parsippany, New Jersey 07054).

Patient monitoring

Clinical Research Coordinators (CRCs) visited patients daily during inpatient hospitalization. After discharge the CRC’s called the patients weekly to monitor compliance and for any complications. The patients were met by the CRC’s again at the time of the follow-up ultrasound. Additionally, patients kept daily diaries of the doses and times of administration of their study drug along with any other drugs they were taking, and any complications and return visits to doctors or hospitals. Telephone interviews were conducted by the CRCs after 6 and 12 months to detect any delayed complications or VTE events.

Examination for deep vein thrombosis and pulmonary embolus

Patients underwent bilateral duplex sonography to evaluate any clinical suggestions of DVT or if asymptomatic on day 28 ± 2 following surgery. Gray scale, color, and spectral Doppler sonography with augmentation were performed of the bilateral common femoral veins, deep femoral veins, superficial femoral veins, popliteal veins, proximal greater saphenous veins, anterior and posterior tibial veins, and peroneal veins. Three highly trained technologists were involved in this study applied the Practice Guidelines and Technical Standards of the American College of Radiology, revised 2010. Ventilation/perfusion lung scan or computerized axial tomography angiogram was performed for evaluation of symptoms of pulmonary embolus. Radiology technicians and the radiologists were blinded to patient randomization.

Quality assurance

The Protocol Committee reviewed data weekly. The Data and Safety Monitoring Board (DSMB) examined blinded data every three months with authority to stop the study if deemed necessary.

Participant retention

Patients were removed from the study drug, but not from the study, if they reached a composite endpoint or if they elected to discontinue the study drug, including those patients who required change in their anticoagulation for ancillary medical reasons.

Protocol violations and adverse events

The Protocol Committee reviewed in blinded fashion all potential protocol violations and adverse events. The likelihood that there be a relationship between the reported events and the study drugs was assigned as being not related, unlikely related, possibly related, probably related or related. A major adverse event was defined as one that required medical or surgical intervention while in hospital, delayed discharge, or prompted return to office or hospital for reevaluation (whether or not intervention was required).

Hemorrhagic complications were classified as major or minor. A minor hemorrhage was one that was observed but required no intervention, such as epistaxis or venipuncture site hematoma. It may have been significant enough to warrant discharge delay or prompt a visit to the doctor or hospital, but with no intervention required. A major hemorrhage would include any fatal bleed or symptomatic bleed into critical area or organ requiring intervention.

Any major adverse event was reported to the IRB, DSMB and if required to the Federal Drug Administration.

Statistical methods

The study analysis was based upon intention to treat and thus all consented patients were included in the analysis. The primary analysis was based on a dichotomous outcome (i.e. VTE–yes/no) with VTE defined as the composite of DVT or PE or death. Estimates of how many patients were required in each arm to detect a difference were based on prior reported experiences in similar studies. With the goal to demonstrate equality for Arm C (upper one-sided 95 % confidence limit for treatment Arm C minus standard treatment arms A and B with the delta not to exceed 15 %), conservative estimates of DVT rates from prior studies and powered to 90 %, it was concluded that 110 patients were needed per group. As there were fewer endpoint events than expected in the three arms, the Odds Ratio was calculated for the composite endpoints using an exact logistic regression conditional analysis, a technique to be used when the outcomes variable have no observations. The non-inferiority analysis was completed using the Wald non-inferiority test.

A statistician analyzed the outcomes for differences between the study arms, differences within subsets (hip and knee arthroplasty), and differences within arms A, B and C for the primary and secondary endpoints. Multivariate analysis is reported for age, gender, body mass index (BMI), and use of hydroxyethyl starch or NSAIDs. Primary outcome data are stratified for hip vs. knee surgery, symptomatic vs. asymptomatic, and popliteal vein and above (proximal) vs. more distal veins. Secondary endpoints were analyzed for the patients as a total cohort. The p-values for all comparative results were calculated.

This was an open label, assessor-blinded study. All authors had access to the data.

Results

Patient recruitment, randomization and retention

There were 3,860 patients were identified for this study by mailings. There was no response from 1,957 patients. Figure 1 demonstrates the flowchart for the remaining 1,903 patients.
Fig. 1
Fig. 1

Patient enrollment flowchart

Randomization was balanced between the three study arms for hip vs. knee surgery, and for gender, age, BMI and baseline blood studies. (see Tables 3, 4 and 5) Two patients had rheumatoid arthritis. Both were among the hip replacement patients. One of these had surgery for steroid induced avascular necrosis. All other patients had surgery for osteoarthritis.
Table 3

Results of randomization

 

Arm A

Arm B

Arm C

Total

 

n

n

n

n

Hip

54

64

55

173

Knee

64

54

64

182

Total

118

118

119

355

Table 4

Baseline demographics

Demographics

Arm A

Arm B

Arm C

A vs B

A vs C

B vs C

p value

p value

p value

Hips

% Male & Female

31.4/32.4

36.0/31.0

32.6/36.6

0.646

0.827

0.490

Age (yr. ± 1 SD)

59.5 (8.6)

60.5 (6.8)

58.9 (9.2)

0.764

0.939

0.553

BMI (± 1SD)

29 (4.5)

30 (4.6)

29.5 (5.6)

0.507

0.837

0.847

Knees

% Male & Female

27.2/37.5

39.5/28.9

33.3/33.7

0.084

0.397

0.369

Age (yr. ± 1 SD)

63.5 (8.2)

63.3 (8.2)

62.3 (8.0)

0.985

0.694

0.791

BMI (± 1 SD)

30.9 (5.9)

31.2 (5.1)

30.8 (5)

0.954

0.993

0.915

Total cohort

% Male & Female

29.3/35.4

37.7/29.7

32.9/34.9

0.111

0.621

0.263

Age (yr. ± 1 SD)

61.6 (8.6)

62 (7.7)

60.7 (8.7)

0.934

0.687

0.467

BMI (± 1SD)

30 (5.4)

30.6 (4.9)

30.2 (5.3)

0.618

0.960

0.783

Table 5

Baseline laboratory results

Laboratory tests

ARM A

ARM B

ARM C

A vs B

A vs C

B vs C

p value

p value

p value

Routine laboratory units (± 1 Standard Deviation)

Hips

Hemoglobin

13.9 (1.2)

14.0 (1.4)

13.7 (1.5)

0.921

0.765

0.525

Platelets (x 1,000)

245.3 (51.8)

244.2 (53.8)

252.3 (47.0)

0.993

0.753

0.685

BUN

17.2 (5.0)

17.5 (4.8)

18.0 (7.3)

0.963

0.722

0.865

Creatinine

0.9 (0.2)

0.9 (0.2)

0.9 (0.2)

0.920

0.692

0.448

Bilirubin

0.5 (0.2)

0.5 (0.3)

0.5 (0.2)

0.689

0.914

0.434

ALT

9.3 (8.5)

11.9 (10.8)

11.5 (8.1)

0.294

0.432

0.962

AST

21.9 (7.0)

22.0 (6.3)

21.9 (5.8)

0.998

0.999

0.994

PTT

27.8 (2.3)

27.4 (2.4)

27.8 (2.2)

0.636

0.993

0.701

INR

1.02 (0.05)

1.01 (0.06)

1.02 (0.06)

0.800

0.099

0.814

Knees

Hemoglobin

13.6 (1.5)

13.9 (1.5)

13.6 (1.3)

0.430

0.994

0.493

Platelets (x 1,000)

257.8 (59.9)

240.0 (47.0)

244.5 (54.6)

0.153

0.346

0.888

BUN

17.9 (5.0)

17.6 (5.4)

18.6 (5.7)

0.963

0.752

0.589

Creatinine

0.8 (0.2)

0.9 (0.2)

0.9 (0.2)

0.434

0.143

0.786

Bilirubin

0.4 (0.3)

0.5 (0.2)

0.5 (0.3)

0.416

0.934

0.638

ALT

12.6 (12.6)

12.8 (12.0)

12.2 (9.7)

0.995

0.970

0.943

AST

22.9 (8.7)

22.3 (8.0)

22.4 (6.6)

0.899

0.929

0.997

PTT

27.6 (2.4)

28.5 (2.3)

27.8 (1.8)

0.067

0.872

0.192

INR

1.00 (0.05)

1.02 (0.04)

1.02 (0.05)

0.217

0.289

0.985

Total cohort

Hemoglobin

13.7 (1.4)

13.9 (1.4)

13.7 (1.4)

0.464

0.921

0.259

Platelets (x 1,000)

252.1 (56.5)

242.0 (50.1)

248.1 (51.2)

0.301

0.829

0.640

BUN

17.6 (5.0)

17.6 (5.1)

18.3 (6.4)

1.000

0.542

0.536

Creatinine

0.9 (0.2)

0.9 (0.2)

0.9 (0.2)

0.790

0.123

0.392

Bilirubin

0.5 (0.3)

0.5 (0.2)

0.5 (0.2)

0.292

1.000

0.293

ALT

11.1 (11.0)

12.4 (11.4)

11.8 (9.0)

0.600

0.853

0.905

AST

22.4 (8.0)

22.2 (7.3)

22.1 (6.2)

0.946

0.943

1.000

PTT

27.7 (2.3)

28.0 (2.4)

27.8 (2.0)

0.596

0.957

0.770

INR

1.01 (0.06)

1.02 (0.05)

1.02 (0.06)

0.767

0.563

0.943

Table 6 demonstrates the patients who withdrew completely from the study and those who withdrew from the study drug but completed the bilateral leg ultrasound as required by the protocol. All patients were included in the Intention to Treat analysis.
Table 6

Patient withdrawals from study

 

Arm A

Arm B

Arm C

Patients withdrawn from study before starting study drug

1

3

5

Patients withdrawn from study after starting study drug

0

3

1

Patients withdrawn before starting study drug; completed ultrasound

1

7

2

Patients withdrawn after starting study drug; completed ultrasound

1

4

2

Prothrombin times reported as International Normalized Ratios (INR)

The INR’s on the day of surgery for patients in Arm C after taking 1.0 mg of warfarin for seven days were ≤ 1.3, with one exception to 1.5. (see Fig. 2) Fig. 3 demonstrates the INR results for patients in Arm A. Each was studied twice per week while on study and the warfarin dose was adjusted according to protocol guidelines. Fig. 4 demonstrates the weekly INR for all patients on Arm C. Five out of 322 INR results that were greater than 1.5.
Fig. 2
Fig. 2

INR’s for patients on Arm C after taking 1 mg warfarin for 7 days before surgery

Fig. 3
Fig. 3

INRs for patients in Arm A receiving variable dose warfarin. These patients were studied twice per week during weeks 1, 2 and 3, as indicated by “week 1a” and “week 1b”, etc

Fig. 4
Fig. 4

All INRs for patients on Arm C

Patients receiving HES or NSAIDs

Patients having hip replacement were more likely to be given HES compared to those having knee replacement. (p <0.05), but there were no differences among the three study arms. (see Table 7) There were no differences within the study groups relative to use of NSAID’s. (data available).
Table 7

Patients receiving hydroxyethyl starch

 

Arm A

Arm B

Arm C

A vs. B

A vs C

B vs C

 

n out of total

n out of total

n out of total

p-value

p-value

p-value

Hips

21 out of 53 (39.6 %)

18 out of 54 (33.3 %)

17 out of 52 (30.4 %)

0.500

0.461

0.944

Knees

1 out of 62 (12.5 %)

2 out of 63 (25 %)

5 out of 62 (62.5 %)

0.576

0.131

0.251

Total

22 out of 115 (19.1 %)

20 out of 117 (17.1 %)

22 out of 114 (19.3 %)

0.687

0.974

0.664

Protocol violations

There were 73 minor protocol violations and 24 major protocol violations, all equally distributed among the study arms (data available) No study violation was associated with an adverse event.

Composite endpoints

Complete bilateral leg ultrasounds were performed for 342 patients distributed equally in the study arms. (data available) There were no patients with VTE at time of discharge. Two patients in Arm C had delayed, asymptomatic, distal ultrasound-detected deep vein thrombosis. One of these patients had knee replacement surgery and the second had hip replacement surgery. They were discharged on days 4 and 5 post-operative respectively. There were no pulmonary emboli and no deaths. The p-values, the Exact Odds ratios with associated confidence limits, the non-inferiority analysis and the 95 % confidence limits are shown in Table 8.
Table 8

Composite endpoints

 

Arm A

Arm B

Arm C

 

n

n

n

DVT proximal

0

0

0

DVT distal

0

0

2

PE

0

0

0

Death on study

0

0

0

Exact Odds Ratios

Unadjusted

Estimate

95 % Confidence Limits

p-value

Odds Ratio

(median unbiased)

  

Arm A vs. Arm C

0.397

0 – 3.344

0.480

Arm B vs. Arm C

0.387

0 - 3.259

0.476

Noninferiority Analysis of Risk Difference

Risk Difference

Estimate

95 % Confidence Limits

p-value*

Arm C vs. Arm A

−0.0180

−0.0428 – 0.0067

<0.0001

Arm C vs. Arm B

−0.0180

−0.0428 – 0.0067

<0.0001

*Using a noninferiority limit of -0.015

Arm C was not to be different from Arms A and B. Because Arm C was non-inferior to Arms A or B, we analyzed equivalency between Arm C and the two arms using the Wald Method for the non-inferiority. Analysis of risk differences between the Arm C minus Arm A and Arm B showed that Arm C is also equivalent to both arm A and arm B, at an equivalency margin of 15 %. (p-value <0.0001; one-sided 95 % CI: -0.0428–0.0067) Thus, there are no statistical differences between Arm C and the other arms of the study.

Adverse events

There were no differences for the surgical estimated blood loss (EBL) or transfusions given among the three study groups. (data available) Patients taking NSAIDs did not have increased hemorrhagic complications. (data available) There were no surgery-related complications such as fracture, dislocation or infection.

More patients in Arm A reported a hemorrhagic event as compared to Arms B and C. The risk of reporting any hemorrhagic complication in Arm A was 1.29 times that of Arm B (95 % CI: 0.61–2.71), and was 1.54 times that of those in Arm C (95 % CI: 0.71–3.33). While there were differences for patients having knee replacement surgery these comparisons did not reach statistical significance for the study groups. (see Table 9) There were no differences of hemorrhagic complications using unadjusted and adjusted odds ratio related to study arm or related to hip vs. knee surgery, adjusted for effects of age, gender and use of HES and NSAID’s. (see Tables 10 and 11) One Arm C patient developed ischemic colitis complicated by gross hematochezia. Despite his taking only 1 mg warfarin daily the INR was prolonged. He was then found to have homozygous vitamin K epoxide reductase–1 (VKORC-1) genome disorder. The event was managed and he remained on study.
Table 9

All hemorrhagic complications including all minor and major bleeds

 

Arm A

Arm B

Arm C

A vs. B

A vs C

B vs C

n out of total

n out of total

n out of total

p-value

p-value

p-value

Hips

9 out of 54

15 out of 54

6 out of 55

0.169

0.386

0.030

(16.7 %)

(27.8 %)

(10.9 %)

Knees

20 out of 64

8 out of 64

12 out of 64

0.013

0.105

0.333

(31.2 %)

(12.5 %)

(18.7 %)

Total

28 out of 118

23 out of 118

18 out of 119

0.347

0.070

0.375

(23.7 %)

(19.5 %)

(15.1 %)

Table 10

Unadjusted estimated effect of treatment on hemorrhagic complications

 

Unadjusted OR (95 % CI)

p-value

Fondaparinux vs. variable dose warfarin

Both

1.29 (0.61-2.71)

0.709

 

Hip

0.45 (0.14-1.42)

0.236

 

Knee

3.18 (1.07-9.45)

0.034

Fixed dose warfarin vs. variable dose warfarin

Both

0.83 (0.38-1.84)

0.854

 

Hip

0.38 (0.12-1.24)

0.134

 

Knee

1.78 (0.57-5.62)

0.463

Fixed dose warfarin vs. fondaparinux

Both

0.65 (0.30-1.40)

0.384

 

Hip

0.84 (0.23-3.10)

0.946

 

Knee

0.56 (0.21-1.47)

0.338

Table 11

Estimate of treatment effect of all hemorrhagic complication stratified for hip vs knee adjusted for effects of age, gender, and NSAID and hetastarch used

 

Adjusted odds ratio(95 % CI)

p-value

Hip

Fondaparinux vs. variable dose warfarin

0.45 (0.14-1.44)

0.238

 

Fixed dose warfarin vs. variable dose warfarin

0.40 (0.12-1.32)

0.170

 

Fixed dose warfarin vs. fondaparinux

0.89 (0.24-3.3645)

0.978

Knee

Fondaparinux vs. variable dose warfarin

3.45 (1.15-10.32)

0.022

 

Fixed dose warfarin vs. variable dose warfarin

1.78 (0.56-5.68)

0.471

 

Fixed dose warfarin vs. fondaparinux

0.52 (0.20-1.36)

0.248

Four major adverse events occurred. Table 12 demonstrates the distribution of these events as being possibly related, probably related or related to study drugs. The two “probably related” leg hematomas occurred while the patients were in the hospital. The other two events occurred following discharge from the hospital.
Table 12

Major complications related to study drugs

Relationship to study drug

n

Description

Study arm

Possibly related

1

Painless hematochezia following hard bowel movement (minor)

B

Probably related

1

Hematoma, operative leg, from post-op trauma (minor; delayed discharge)

B

1

Hematoma evaluated, no intervention required (minor; delayed discharge)

B

Related

1

Hemorrhage with ischemic colitis. INR prolonged on 1 mg warfarin

C

  

per day due to VKORC-1 genome disorder. (major; readmitted to hospital)

 

D-dimer

Patients having knee replacement were more likely to have elevated D-dimer at the completion of the study compared to those having hip surgery. (p <0.0001) (see Table 13) There were no differences relative to the arms of the study. There were no delayed onset VTE events after 6 and 12 months from completion of study.
Table 13

Changes of D-dimer from baseline negative/indeterminate to >1000 μgm/dl after 28 ± 2 days

 

Changed from 0 – 999 at baseline to >1,000 after 28 ± 2 days

Yes

No

p-value for hip vs. knee

n (%)

n (%)

 

Hips

45 (31.5 %)

98 (68.5 %)

<0.0001

Knees

116 (70.7 %)

48 (29.3 %)

 

Patients with elevated D-dimer (>1,000 μg/dL) at follow-up, stratified for knee vs. hip and study arm

 

Arm A

Arm B

Arm C

A vs. B

A vs. C

B vs. C

p-value

p-value

p-value

Knees

12 of 47 (25.5 %)

15 of 50 (30.0 %)

18 of 46 (39.1 %)

0.624

0.163

0.348

Hips

41 of 54 (75.9 %)

38 of 59 (64.4 %)

37 of 51 (72.5 %)

0.185

0.693

0.362

Total

53 of 101 (52.5 %)

53 of 109 (48.6 %)

55 of 97 (56.7 %)

0.577

0.551

0.247

Discussion

Patients given no anticoagulants after hip or knee arthroplasty experience high rates of postoperative VTE [23–28]. Heretofore, commonly used anticoagulants reduced the frequency of postoperative VTE to 4–6 %. A meta-analysis of modern low molecular weight heparins, oral Xa inhibitors or oral IIa inhibitors included 47 clinical trials and observational studies involving 44,844 patients demonstrated rates of symptomatic DVT prior to discharge of 1.09 % for patients having TKA and 0.53 % for patients having THA, with heterogeneity of results among the included reports [29]. The current study shows that our fixed low dose warfarin regimen approximates the same level of benefit.

The two agents used in this current study as controls can be considered as among the available standards-of-care agents available for DVT prophylaxis. Variable dose warfarin has been used for many years, and is effective with the current target range of INR [30, 31]. Fondaparinux, a synthesized pentasaccaride with anti-factor Xa activity, was among the newer agents with VTE prophylaxis activity when this study was designed [22, 32–35].

As in our previous orthopedic studies and as with other investigators we selected a preoperative lead-time of 7 days for the fixed low dose warfarin used in this study [8, 11, 36, 37]. In an earlier central venous catheter study we choose 3 days [6]. We would not expect this low dose warfarin therapy to succeed if started following surgery, even though in one series it did succeed even when therapy was begun after central venous catheter insertion [12, 38–41].

There were two previous smaller but similarly structured studies that derived negative results for low dose warfarin following major orthopedic surgery. Poller, et al., in a report of 68 evaluable patients randomized to receive either warfarin 1 mg daily starting 7 days preoperatively or 5,000 units heparin starting 2 h preoperatively, with venography as the diagnostic tool [36]. Fordyce, et al., studied 148 patients having primary hip replacement surgery were randomized to take 1 mg warfarin starting 7 days prior to surgery or to be non-treated controls. Iodine-125 labeled fibrinogen uptake (with venography confirmation for positive femoral vein uptake) was used for detection of DVT [37].

Differences in outcomes may be dependent upon the DVT detection techniques applied. Color Doppler ultrasound was used in this study to detect DVT. Ultrasound imaging is accepted for diagnosing DVT with sensitivity and specificity for detection of proximal deep vein thrombosis is over 95 %. In studies of asymptomatic patients, the sensitivity the test has been variable. Nevertheless, a single negative complete lower limb examination is considered sufficient to exclude clinically important DVT [42–44]. New symptoms always require further imaging. In the current study patients were called at 6 and 12 months to detect any delayed symptomatic VTE events in order to detect any false negative results.

On the other hand, venography, often considered the gold standard for DVT detection studies, is far from the ideal diagnostic procedure. Venography-dependent studies often have significant numbers of patients who never get the venogram, have unilateral studies instead of bilateral studies, or are rejected by the adjudicating committees as technically inadequate [24, 45–50]. Venography also involves added risks for patients with allergic and renal reactions, skin necrosis if contrast dye extravasates and post-injection phlebitis in up to 2 % of patients in whom conventional ionic contrast agents are used. Even with use of lower osmolar contrast agents, minor side effects occur in about 20 % of patients undergoing venography. Fibrinogen scanning may have been supersensitive.

Also, the current study was performed in a hospital with a high volume of joint replacement surgery, wherein optimal non-pharmacologic DVT prophylaxis is also applied along with chemoprophylaxis. Patients are told to discontinue smoking and estrogen supplements prior to surgery, to walk the day of surgery, and wear bilateral pneumatic compression stockings in hospital followed by elastic compression stockings after discharge until follow-up visits. Perhaps some of these elements may contribute to differences between the study outcomes.

There are clinically relevant elements within any study that cannot be stratified or controlled. In this study tourniquets were used for all patients having knee replacement, and it is assumed that the time the tourniquets were applied was equal for each study group [50]. Volume expansion by crystalloids can influence post-operative coagulation; it is assumed that the volume expansions were equivalent for each study group [51]. HES can have effects upon the clotting system [52, 53]. There were no differences for the use of HES among the three arms of this study. Also, as there are over 100 drugs, foods and supplements reported to interfere with platelet function, with unclear clinical significance for most, it would have been difficult to control for all of these agents [54]. It was decided by the protocol writing committee to track and analyze six of the more commonly used NSAIDs.

A positive D-dimer assay after conclusion of therapy for acute DVT or PE has been previously reported to be predictive of relapse of VTE. In one such study following one month of therapy for DVT, 39 % of patients had elevated D-dimer and seven of these patients went on to have recurrent VTE [55]. There is also increasing recognition that longer prophylactic therapy is beneficial in the post-operative setting [56–62]. The current study prescribed that all study patients have measurements of D-dimer at the end of the treatment. No patient had delayed onset VTE when called 6 months and 12 months following completion of one month of therapy. Thus, in this study a positive D-dimer at the conclusion of therapy had no predictive value for delayed onset VTE after prolonger therapy of one month.

This proof of concept study builds upon prior studies examining low dose schedules for postoperative VTE chemoprophylaxis with warfarin. Trail limitations include that this is a single institution, open label but assessor-blind study study. A similar multi-institutional study with a larger number of patients would be welcomed. Perhaps it would also be useful to attempt the next such study with combined Doppler ultrasound and venography detection for DVT to confirm adequacy of Doppler ultrasound.

In conclusion, the three regimens in this study offer effective prophylaxis against thromboembolic disease following elective arthroplasty of hips and knees. It appears that fixed low dose warfarin when used as described is equivalent to two of the more intense regimens. By extending postoperative anticoagulation to four weeks there appears to be less chance for delayed VTE, even if there is a positive D-dimer at conclusion of treatment. Each regimen carries some risk and some inconvenience for the patient. The fixed low dose warfarin regimen herein described saves the patients the inconvenience of multiple blood draws, but does not eliminate that need completely, as demonstrated in our patient with vitamin K epoxide reductase genome disorder. Nevertheless, it should carry minimal hemorrhagic potential and require reduced laboratory support. It should be less expensive and easier to administer than other protocols using anti-Xa and anti-IIa agents, which has implications for health care costs.

Declarations

Acknowledgements

We acknowledge the additional statistical analysis by John Griffith, PhD and Ling Li, MPH. Elizabeth Stroch provided editorial review, supported by the Department of Orthopedic Surgery, New England Baptist Hospital. Funding sources for this study included the New England Baptist Hospital and its Elizabeth Alexander Stent Fund, The Cancer Center Research Foundation and The Foundation for Hematology Research. These organizations had no input into the design and conduct of this study; collection, management, analysis and interpretation of the data; or preparation, review or approval of this manuscript. Material support for this study came from the supplier of fondaparinux, GlaxoSmithKline, which was aware of the study, but had no input into the study conception, design, conduct, analysis, or interpretation of the study data; nor preparation, statistical analysis, review or approval of this manuscript.

Authors’ Affiliations

(1)
Departments of Medicine, New England Baptist Hospital, Boston, MA, USA
(2)
Orthopedic Surgery, New England Baptist Hospital, Boston, MA, USA
(3)
Diagnostic Radiology, New England Baptist Hospital, Boston, MA, USA
(4)
Research, New England Baptist Hospital, Boston, MA, USA
(5)
Harvard Medical School, Boston, MA, USA
(6)
University of New Mexico Cancer Center, 1201 Camino de Salud, Albuquerque, NM 87131, USA
(7)
Tufts University School of Medicine, Boston, MA, USA

References

  1. Baptiste G, Bern MM, Bothe Jr A, Bistrian BR, Blackburn G. Low Antithrombin III in morbid obesity: improved levels following weight loss. J Parenter Enteral Nutr. 1983;7:447–9.View ArticleGoogle Scholar
  2. Bern MM, Bothe Jr A, Bistrian B, Batiste G, Haywood E, Blackburn G. Effects of low-dose warfarin on antithrombin III levels in morbidly obese patients. Surgery. 1983;94:78–83.PubMedGoogle Scholar
  3. Francis CW, Marder VJ, Evarts CM, Yaukoolbodi S. Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding. JAMA. 1983;249:374–8.PubMedView ArticleGoogle Scholar
  4. Bern MM, Bothe A, Bistrian B, Champagne CD, Keane MS, Blackburn G. Prophylaxis against central vein thrombosis with low-dose warfarin. Surgery. 1986;99:216–21.PubMedGoogle Scholar
  5. Poller L, McKernan A, Thomson JM, Elstein M, Hirsh PJ, Jones JB. Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. Br Med J (Clin Res Ed). 1987;295:1309–12.View ArticleGoogle Scholar
  6. Bern MM, Lokich JJ, Wallach SR, Bothe Jr A, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C. Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Int Med. 1990;112:423–8.PubMedView ArticleGoogle Scholar
  7. MacCallum PK, Thomson JM, Poller L. Effects of fixed minidose warfarin on coagulation and fibrinolysis following major gynaecological surgery. Thromb Haemost. 1990;64:511–5.PubMedGoogle Scholar
  8. Bern MM, Bierbaum B, Wetzner S, Brennan W, McAlister S. Very low dose warfarin as prophylaxis against ultrasound detected deep vein thrombosis following primary hip replacement. Am J Hemat. 2002;7:69–74.View ArticleGoogle Scholar
  9. Mismetti P, Mille D, Laporte S, for the CIP Study Group. Low-molecular weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: A pilot randomized trial. Haematologica. 2003;88:67–74.PubMedGoogle Scholar
  10. Vives MJ, Hozack WJ, Sharkey PF, Moriarty L, Sokoloff B, Rothman RH. Fixed minidose versus adjusted low-dose warfarin after total joint arthroplasty: a randomized prospective study. J Arthroplasty. 2001;16:1030–7.PubMedView ArticleGoogle Scholar
  11. Bern MM, Deshmukh RV, Nelson R, Bierbaum BE, Sevier N, Howie N, Losina E, Katz JN. Low-dose warfarin coupled with lower leg compression is effective prophylaxis against thromboembolic disease after hip arthroplasty. J Arthroplasty. 2007;22:644–50.PubMedView ArticleGoogle Scholar
  12. Lavau-Denes S, Lacroix P, Maubon A, Preux PM, Genet D, Vénat-Bouvet L, Labourey JL, Martin J, Slaouti P, Tubiana-Mathieu N. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study. Cancer Chemother Pharmacol. 2013;72:65–73.PubMedView ArticleGoogle Scholar
  13. Holm J, Berntorp E, Carlsson R, Erhardt L. Low-dose warfarin decreases coagulability without affecting prothrombin complex activity. J Intern Med. 1993;234:303–8.PubMedView ArticleGoogle Scholar
  14. Boraks P, Seale J, Price J, Bass G, Ethell M, Keeling D, Mahendra P, Baglin T, Marcus R. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol. 1998;101:483–6.PubMedView ArticleGoogle Scholar
  15. Bach AU, Anderson SA, Foley AL, Williams EC, Suttie JW. Assessment of vitamin K status in human subjects administered “minidose” warfarin. Am J Clin Nutr. 1996;64:894–902.PubMedGoogle Scholar
  16. Uehara S, Gotoh K, Handa H, Honjo K, Hirayama A. Process of carboxylation of glutamic acid residues in th Gla domain of human des-gamma-carboxyprothrombin. Clin Chim Acta. 1999;289:33–44.PubMedView ArticleGoogle Scholar
  17. Stenflo J, Fernlurd P, Egon W, Roepstorff P. Vitamin K-dependent modification of glutamic acid residues in prothrombin. Proc Natl Acad Sci U S A. 1974;71:2730–3.PubMed CentralPubMedView ArticleGoogle Scholar
  18. Tuhy PM, Bloom JW, Mann KG. Decarboxylation of bovine prothrombin fragment 1 and prothrombin. Biochemistry. 1979;18:5842–8.PubMedView ArticleGoogle Scholar
  19. Furie B, Furie BC. The molecular basis of blood coagulation. Cell. 1988;53:505–18.PubMedView ArticleGoogle Scholar
  20. Colpitts TL, Prorok M, Castellino FJ. Binding of calcium to individual gamma-carboxyglutamic acid residues of human protein C. Biochemistry. 1995;34:2424–30.PubMedView ArticleGoogle Scholar
  21. Ratcliffe JV, Furie B, Furie BC. The importance of specific gamma-carboxyglutamic acid residues in prothrombin. J Biol Chem. 1993;268:24339–45.PubMedGoogle Scholar
  22. Rachidi S, Aldin ES, Greenberg C, Sachs B, Streiff M, Zeidan AM. The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. Expert Rev Hematol. 2013;6:677–95. doi:10.1586/1747408.PubMed CentralPubMedView ArticleGoogle Scholar
  23. Anderson Jr FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier ADalen JE. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151:933–8.PubMedView ArticleGoogle Scholar
  24. Piovella F, Wang CJ, Lu H, Lee K, Lee LH, Turpie AGG, Gallus AS, Planes A, Passera R Rouillon A for the AIDA Investigators. Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost. 2005;3:2664–70.PubMedView ArticleGoogle Scholar
  25. Turpie AG, Levin MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M. A randomized controlled trial of low molecular–weight heparin (enoxaparin) to prevent deep vein thrombosis in patients undergoing elective hip surgery. N Eng J Med. 1986;315:925–9.View ArticleGoogle Scholar
  26. Hoek JA, Nurmohamed MT, Hamelyck KJ, Marti RK, Knipscheer HC, ten Cate H, Büller HR, Magnani HN, ten Cate JW. Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid. Thrombo Haemost. 1992;67:28–32.Google Scholar
  27. McKenna K, Bachmann F, Kaushal SP, Galante JO. Thromboembolic disease in patients undergoing knee replacement. J Bone Joint Surg Am. 1976;58:928–32.PubMedGoogle Scholar
  28. Stulberg BN, Insal JN, Willaims GW, Ghelman B. Deep-vein thrombosis following total knee replacement. An analysis of six hundred and thirty-eight arthroplasties. J Bone Joint Surg Am. 1984;66:194–201.PubMedGoogle Scholar
  29. Januel JM, Chen G, Ruffieux C, Quan H, Douketis JD, Crowther MA, Colin C, Ghali WA, Burnand B; IMECCHI Group. Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review. JAMA. 2012;307:294–303.PubMedView ArticleGoogle Scholar
  30. Enyart JJ, Jones RJ. Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery. Ann Pharmacother. 2005;39:1002–7.PubMedView ArticleGoogle Scholar
  31. Kwong LM. Comparative safety and efficacy of antithrombotics in the management of venous thromboembolism after knee and hip replacement surgery: focus on rivaroxaban. Clin Pharmacol. 2013;5:143–8.PubMed CentralPubMedGoogle Scholar
  32. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for prevention of venous thromboembolism in major orthopaedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162:1833–40.PubMedView ArticleGoogle Scholar
  33. Eriksson BI, Bauer KA, Lassen MR, Turpie AG, Steering Committee for of the Pentasaccaride in Hip-Fracture Study Group. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip fracture surgery. N Engl J Med. 2001;345:1298–304.PubMedView ArticleGoogle Scholar
  34. Bauer KA, Eriksson BI, Lassen MR, Turpie AG, Steering Committee for of the Pentasaccaride in Hip-Fracture Study Group. Fondaparinux compared to enoxaparin for the prevention of venous thromboembolism after elective knee surgery. N Engl J Med. 2001;345:1305–10.PubMedView ArticleGoogle Scholar
  35. Tran AH, Lee G. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery. Ann Pharmacother. 2003;37:1632–43.PubMedView ArticleGoogle Scholar
  36. Poller L, Thomson JM, MacCallum PK, Nicholson DA, Weighill FJ, Lemon JG. Minidose warfarin and failure to prevent deep vein thrombosis after joint replacement surgery despite inhibiting the postoperative rise in plasminogen activator inhibitor activity. Clin Appl Throm Hemost. 1995;1:267–73.View ArticleGoogle Scholar
  37. Fordyce MJ, Baker AS, Staddon GE. Efficacy of fixed minidose warfarin prophylaxis in total hip replacement. BMJ. 1991;303:219–20.PubMed CentralPubMedView ArticleGoogle Scholar
  38. Heaton DC, Han DY, Inder A. Minidose (1mg) warfarin as prophylaxis for central vein catheter thrombosis. Int Med J. 2002;3:84–8.View ArticleGoogle Scholar
  39. Couban D, Goodyear M, Burnell M, Dolan D, Wasi P, Barnes D, Macleod D, Burton E, Andreou P, Anderson DR. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol. 2005;23:4063–9.PubMedView ArticleGoogle Scholar
  40. Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea DW, Shepherd S, Stanley A, Sweeney A, Wilde J, Wheatley K, WARP Collaborative Group, UK. Warfarin thromboprophylaxis in caner patient with central venous catheters (WARP): an open-label randomized trial. Lancet. 2009;373:567–74. doi:10.1016/S0140-6736(09)60205-1.PubMedView ArticleGoogle Scholar
  41. Ruud E, Holmstrøm H, De Lange C, Hogstad EM, Wesenberg F. Low-dose warfarin for the prevention of central line-associated thrombosis in children with malignancies—a randomized, controlled study. Acta Paediatr. 2006;95:1053–9.PubMedView ArticleGoogle Scholar
  42. Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Gray L, Clement C, Robinson KS, Lewandorski B. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet. 1997;350:1795–8.PubMedView ArticleGoogle Scholar
  43. Fraser JD, Anderson DR. Deep vein thrombosis: recent advances and optimal investigation with US. Radiology. 1999;211:9–14.PubMedView ArticleGoogle Scholar
  44. Subramaniam RM, Heath R, Chou T, Cox K, Davis G, Swarbrick M. Deep venous thrombosis: withholding anticoagulation therapy after negative complete lower limb US findings. Radiology. 2005;237:348–52.PubMedView ArticleGoogle Scholar
  45. Bergqvist D, Benoni G, Björgell O, Fredin H, Hedlundh U, Nicolas S, Nisson P, Nylander G. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996;335:696–700.PubMedView ArticleGoogle Scholar
  46. Planes A, Vochelle N, Fagola M, Bellaud M. Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group. Blood Coagul Fibrinolysis. 1998;9:499–505.PubMedView ArticleGoogle Scholar
  47. Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet. 1996;347:635–9.PubMedView ArticleGoogle Scholar
  48. Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, Holmqvist A, Mant M, Dear R, Baylis B, Mah A, Brant R. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs. warfarin in hip arthroplasty patients: a double- blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Int Med. 2000;160:2199–207.View ArticleGoogle Scholar
  49. Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L’Espérance B, Demers C, Kassis J, Cruickshank M, Whitman L, Delorme F. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Int Med. 1996;124:619–26.PubMedView ArticleGoogle Scholar
  50. Aglietti P, Baldini A, Vena LM, Abbate R, Fedi S, Falciani M. Effect of tourniquet use on activation of coagulation in total knee replacement. Clin Orthop Relat Res. 2000;169–177.Google Scholar
  51. Weiss G, Lison S, Spannagl M, Heindl B. Expressiveness of global coagulation parameters in dilutional coagulopathy. Br J Anaesth. 2010;105:429–36.PubMedView ArticleGoogle Scholar
  52. Schramko A, Suojaranta-Ylinen R, Kuitunen A, Raivio P, Kukkonen S, Niemi T. Hydroxyethylstarch and gelatin solutions impair blood coagulation after cardiac surgery: a prospective randomized trial. Br J Anaesth. 2010;104:691–7.PubMedView ArticleGoogle Scholar
  53. Haisch G, Boldt J, Krebs C, Suttner S, Lehmann A, Isgro F. Influence of a new hydroxyethylstarch preparation (HES 130/0.4) on coagulation in cardiac surgical patients. J Cardiothorac Vasc Anesth. 2011;25:755–7.View ArticleGoogle Scholar
  54. Konkle B. Acquired disorders of platelet function. American Society of Hematology: Hematology; 2011. p. 391–6.Google Scholar
  55. Kuruvilla J, Wells PS, Morrow B, MacKinnon K, Keeney M, Kovacs MJ. Prospective assessment of the natural history of positive D-dimer results in persons with acute venous thromboembolism (DVT or PE). Thromb Haemost. 2003;89:284–7.PubMedGoogle Scholar
  56. Prandoni P, Bruchi O, Sabbion P, Tanduro C, Scudeller A, Sardella C, Errigo G, Pietobelli F, Maso G, Girolami A. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Arch Intern Med. 2002;162:1966–71.PubMedView ArticleGoogle Scholar
  57. Eriksson BI, Lassen MR, for the PENTasaccharide in Hip-Fracture Surgery Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery. Arch Intern Med. 2003;163:1337–42.PubMedView ArticleGoogle Scholar
  58. Cohen AT, Bailey CS, Alikhan R, Cooper DJ. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty-a meta-analysis. Thromb Haemost. 2001;85:940–1.PubMedGoogle Scholar
  59. Sobieraj DM, Lee S, Coleman CI, Tongbram V, Chen W, Colby J, Makanji S, Ashaye AO. Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery. Ann Intern Med. 2012;156:720–7.PubMedView ArticleGoogle Scholar
  60. Eriksson BI. Improvements in the prevention of postoperative venous thromboembolism in hip fracture patients. Orthopedics. 2003;26 suppl 8:s851–8.PubMedGoogle Scholar
  61. Turpie AG. Fondaparinux: a factor Xa inhibitor for antithrombotic therapy. Expert Opin Pharmacother. 2004;5:1373–84.PubMedView ArticleGoogle Scholar
  62. Cohen AT, Khushal A. Extended thromboprophylaxis following lower limb arthroplasty: what do the clinical trials mean? Haemostasis. 2000;30 suppl 2:88–94.PubMedGoogle Scholar

Copyright

© Bern et al. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement

Thrombosis Journal

ISSN: 1477-9560

Contact us